A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E.

DOI PDF 33 Citations
  • C Traversari
    Ludwig Institute for Cancer Research, Brussels Branch, Belgium.
  • P van der Bruggen
    Ludwig Institute for Cancer Research, Brussels Branch, Belgium.
  • I F Luescher
    Ludwig Institute for Cancer Research, Brussels Branch, Belgium.
  • C Lurquin
    Ludwig Institute for Cancer Research, Brussels Branch, Belgium.
  • P Chomez
    Ludwig Institute for Cancer Research, Brussels Branch, Belgium.
  • A Van Pel
    Ludwig Institute for Cancer Research, Brussels Branch, Belgium.
  • E De Plaen
    Ludwig Institute for Cancer Research, Brussels Branch, Belgium.
  • A Amar-Costesec
    Ludwig Institute for Cancer Research, Brussels Branch, Belgium.
  • T Boon
    Ludwig Institute for Cancer Research, Brussels Branch, Belgium.

Abstract

<jats:p>We have reported the identification of human gene MAGE-1, which directs the expression of an antigen recognized on a melanoma by autologous cytolytic T lymphocytes (CTL). We show here that CTL directed against this antigen, which was named MZ2-E, recognize a nonapeptide encoded by the third exon of gene MAGE-1. The CTL also recognize this peptide when it is presented by mouse cells transfected with an HLA-A1 gene, confirming the association of antigen MZ2-E with the HLA-A1 molecule. Other members of the MAGE gene family do not code for the same peptide, suggesting that only MAGE-1 produces the antigen recognized by the anti-MZ2-E CTL. Our results open the possibility of immunizing HLA-A1 patients whose tumor expresses MAGE-1 either with the antigenic peptide or with autologous antigen-presenting cells pulsed with the peptide.</jats:p>

Journal

Citations (33)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top